Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

he requirements and plans for regulatory filings and approvals for clofarabine in additional indications. These risks and uncertainties include, among others, the timing and results of clinical studies for clofarabine; the timing of discussions with the EMEA and FDA regarding clinical study results and approval of clofarabine in additional indications; the timing and content of decisions by the EMEA and FDA related to clinical trials and approval of clofarabine in additional indications; the actual efficacy and safety of clofarabine for the indications in which it is being tested; and the risks and uncertainties described in reports filed by Genzyme with the U.S. Securities and Exchange Commission, including without limitation the factors discussed under the caption "Risk Factors" in Genzyme's Annual Report on Form 10-K for the year ended December 31, 2007. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Genzyme(R) and Evoltra(R) are registered trademarks of Genzyme Corporation or its subsidiaries. All rights reserved.

Media Contact: Investor Contact:

Maria Cantor Patrick Flanigan

(617) 768-6690 (617) 768-6563


'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Budding Biomedical Scientists ... University School participated in the Scientific Enrichment ... University’s School of Medicine . , ... unparalleled professional experience in the sciences and brings ... faculty and students for both academic and career ...
(Date:8/26/2014)... , Aug. 26, 2014  NeuroSigma, Inc., a ... to develop bioelectronic technologies, today announced that it has ... U.S. Securities and Exchange Commission relating to a proposed ... of shares to be offered and the price range ... Jefferies LLC will act as the book-running ...
(Date:8/26/2014)... Aug. 26, 2014 An analysis by Replikins, ... all Mers CoV virus strains has revealed ... to 2012.  This conservation and sharing of specific Replikin ... CoV Blocker-Vaccine™ candidate, as it did for the H5N1 ... of which have been found to be effective (1,2). ...
(Date:8/26/2014)... engineers from Singapore has successfully piloted the world,s ... communications. , With the weight of payloads being ... lightweight, low power-consuming, wireless communication system to do ... been a challenge for system designers. , The ... Nanyang Technological University in Singapore launched VELOX-I, which ...
Breaking Biology Technology:Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2ZigBee in the Sky 2
... /PRNewswire/ - Cytochroma today announced that it,has appointed ... Affairs and Quality Assurance. Dr. Engel brings to ... and quality assurance,and will be responsible for directing ... that the Company has appropriate quality,systems in place. ...
... VLP vaccines gains momentum with launch of a Phase ... IIa study of Seasonal Influenza Vaccine, ... ) announced today vaccination of healthy volunteers in a Phase,II ... The Phase IIa randomized, placebo controlled clinical trial will,evaluate the ...
... Sept. 16 Accuray,Incorporated (Nasdaq: ARAY ), a ... its president and chief executive officer, Euan S.,Thomson, Ph.D., ... Sciences,Conference in New York City, on Thursday, September 25, ... live webcast of the presentation will be available online ...
Cached Biology Technology:Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance 2Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 2Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 3Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 4Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 5Accuray Incorporated's CEO to Speak at UBS Global Life Sciences Conference 2
(Date:8/27/2014)... researchers have identified a gene that could help scientists ... protein in the cell membrane of plants that senses ... conservation machinery accordingly. , "It,s similar to a ... at Duke. , The findings, which appear Aug. ... it easier to feed the world,s growing population in ...
(Date:8/27/2014)... requires nerve cells to rearrange existing patterns of activity ... patterns, a study of monkeys has found. The scientists ... electrical activity of brain cell networks. The study was ... "We looked into the brain and may have seen ... said Aaron Batista, Ph.D., an assistant professor at the ...
(Date:8/27/2014)... invasive grass species frequently found in forests has created ... on American toads, a new University of Georgia study ... to the U.S. in the early 1900s, is one ... to more than a dozen states in the past ... and in forests, it can survive in widely diverse ...
Breaking Biology News(10 mins):Water 'thermostat' could help engineer drought-resistant crops 2Scientists plug into a learning brain 2Scientists plug into a learning brain 3More wolf spiders feasting on American toads due to invasive grass, UGA study shows 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 3
... One fifth of the standard dose of a commonly ... the full dose. This new finding should allow scarce ... in Africa. In a study initiated by the ... research arm of Doctors Without Borders/Mdecins Sans Frontires), and ...
... Institute,s Linheng Li Lab has identified the precise location of ... today in the Advance Online Publication of Nature . ... Institute,s support facilities to develop a new technology ex ... the dynamic behavior of stem cells. This technology enabled the ...
... University,s School of Biomedical Engineering and Science,s Center for Injury ... 2008. The Office of the Deputy Chief of ... the award for research that could ultimately help save eyesight ... The center was selected from 57 applicants from around ...
Cached Biology News:Stowers Institute's Linheng Li Lab expands understanding of bone marrow stem cell niche 2New dummy design and development wins US Department of Defense award 2
...
... Digital Sight DS-U2 camera controller is the successor ... designed to interface any of the cameras in ... computer through a USB2.0 interface. The DS-U2 transmits ... cumbersome installation by equipping both hub and mass ...
This unique buffer provides a gentle method for removal of primary and secondary antibodies to allow several reprobings on the same membrane. Gentle buffer will not alter the antigen for subsequent i...
...
Biology Products: